首页 > 最新文献

Hepatology Forum最新文献

英文 中文
Optimal testing strategies for incidental anti-mitochondrial M2 antibody-positive patients. 针对偶发性抗线粒体 M2 抗体阳性患者的最佳检测策略。
IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-16 eCollection Date: 2024-01-01 DOI: 10.14744/hf.2023.2023.0043
Kristina Emsell-Needham, Sujoy Khan
{"title":"Optimal testing strategies for incidental anti-mitochondrial M2 antibody-positive patients.","authors":"Kristina Emsell-Needham, Sujoy Khan","doi":"10.14744/hf.2023.2023.0043","DOIUrl":"10.14744/hf.2023.2023.0043","url":null,"abstract":"","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 1","pages":"49"},"PeriodicalIF":1.2,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809336/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571383","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prevalence of hepatic steatosis and fibrosis in apparently healthy airline pilots: A transient elastography study. 表面健康的飞行员肝脏脂肪变性和纤维化的发生率:瞬态弹性成像研究
IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-16 eCollection Date: 2024-01-01 DOI: 10.14744/hf.2023.2023.0050
Piercarlo Minoretti, Andrés S Santiago Sáez, Ángel F García Martín, Miryam Liaño Riera, Manuel Gómez Serrano, Enzo Emanuele

Background and aim: Airline pilots (APs) are often characterized by a sedentary lifestyle, predisposing them to adverse cardiometabolic consequences. In this cross-sectional study, we used transient elastography (TE) to investigate the prevalence of hepatic steatosis and fibrosis among apparently healthy APs.

Materials and methods: The study cohort consisted of 137 male APs of Caucasian descent who voluntarily underwent TE. To evaluate the extent and severity of hepatic steatosis and fibrosis, we employed established cutoff values for the controlled attenuation parameter (CAP) and liver stiffness measurement (LSM).

Results: Of the APs, 34 (24.8%) were diagnosed with TE-defined steatosis. Specifically, 25 APs (18.2%) exhibited mild steatosis, 6 (4.4%) moderate steatosis, and 3 (2.2%) severe steatosis. The majority of participants (80 APs or 58.4%) showed no signs of liver fibrosis based on LSM values. However, 49 APs (35.8%) were diagnosed with mild fibrosis (F1), 7 (5.1%) with significant fibrosis (F2), and one (0.7%) with advanced fibrosis (F3). None of the pilots had F4 (cirrhosis). In multivariable linear regression analysis, BMI was the sole independent predictor of both CAP (β=0.34, p<0.001) and LSM (β=0.41, p<0.001) values in our sample of male APs.

Conclusion: TE is a straightforward and convenient non-invasive method for detecting hepatic steatosis and fibrosis in high-risk occupational groups such as APs.

背景和目的:航空公司飞行员(APs)的生活方式通常以久坐不动为特征,这使他们容易出现不良的心脏代谢后果。在这项横断面研究中,我们使用瞬态弹性成像技术(TE)来调查表面健康的飞行员肝脏脂肪变性和纤维化的患病率:研究队列包括 137 名自愿接受瞬态弹性成像检查的男性白种人后裔 APs。为了评估肝脏脂肪变性和纤维化的范围和严重程度,我们采用了既定的控制衰减参数(CAP)和肝脏硬度测量(LSM)的临界值:结果:34 名 AP(24.8%)被诊断为 TE 定义的脂肪变性。具体来说,25 名 AP(18.2%)表现为轻度脂肪变性,6 名(4.4%)为中度脂肪变性,3 名(2.2%)为重度脂肪变性。根据 LSM 值,大多数参与者(80 位 AP 或 58.4%)没有肝纤维化迹象。然而,有 49 名飞行员(35.8%)被诊断为轻度肝纤维化(F1),7 名飞行员(5.1%)被诊断为重度肝纤维化(F2),1 名飞行员(0.7%)被诊断为晚期肝纤维化(F3)。没有一名飞行员患有 F4(肝硬化)。在多变量线性回归分析中,体重指数是两个 CAP 的唯一独立预测因子(β=0.34,p 结论:TE 是一种直接、方便、非内源性的肝纤维化诊断方法:TE是一种简便易行的非侵入性方法,可用于检测高危职业人群(如飞行员)的肝脂肪变性和肝纤维化。
{"title":"Prevalence of hepatic steatosis and fibrosis in apparently healthy airline pilots: A transient elastography study.","authors":"Piercarlo Minoretti, Andrés S Santiago Sáez, Ángel F García Martín, Miryam Liaño Riera, Manuel Gómez Serrano, Enzo Emanuele","doi":"10.14744/hf.2023.2023.0050","DOIUrl":"10.14744/hf.2023.2023.0050","url":null,"abstract":"<p><strong>Background and aim: </strong>Airline pilots (APs) are often characterized by a sedentary lifestyle, predisposing them to adverse cardiometabolic consequences. In this cross-sectional study, we used transient elastography (TE) to investigate the prevalence of hepatic steatosis and fibrosis among apparently healthy APs.</p><p><strong>Materials and methods: </strong>The study cohort consisted of 137 male APs of Caucasian descent who voluntarily underwent TE. To evaluate the extent and severity of hepatic steatosis and fibrosis, we employed established cutoff values for the controlled attenuation parameter (CAP) and liver stiffness measurement (LSM).</p><p><strong>Results: </strong>Of the APs, 34 (24.8%) were diagnosed with TE-defined steatosis. Specifically, 25 APs (18.2%) exhibited mild steatosis, 6 (4.4%) moderate steatosis, and 3 (2.2%) severe steatosis. The majority of participants (80 APs or 58.4%) showed no signs of liver fibrosis based on LSM values. However, 49 APs (35.8%) were diagnosed with mild fibrosis (F1), 7 (5.1%) with significant fibrosis (F2), and one (0.7%) with advanced fibrosis (F3). None of the pilots had F4 (cirrhosis). In multivariable linear regression analysis, BMI was the sole independent predictor of both CAP (β=0.34, p<0.001) and LSM (β=0.41, p<0.001) values in our sample of male APs.</p><p><strong>Conclusion: </strong>TE is a straightforward and convenient non-invasive method for detecting hepatic steatosis and fibrosis in high-risk occupational groups such as APs.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 1","pages":"7-10"},"PeriodicalIF":1.2,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809345/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571406","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Safety and hemostatic effect of Achillea millefolium L. in localized bleeding. Achillea millefolium L.对局部出血的安全性和止血效果。
IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-16 eCollection Date: 2024-01-01 DOI: 10.14744/hf.2022.2022.0041
Amin Bagheri, Gholamreza Amin, Seyed Mohammad Tavangar, Matineh Heidari, Jamshid Bagheri

Background and aim: This study aims to demonstrate the hemostatic effect of the hydroalcoholic extract of Achillea millefolium L. in localized bleeding and to assess the safety of its topical application on rat liver.

Materials and methods: The aerial parts of A. millefolium were macerated in methanol for two days. Twelve female Wistar rats, weighing 120-220 g, underwent anesthesia and laparotomy. The liver was exposed, and two incisions were made to induce bleeding. One incision was treated with a sponge soaked in A. millefolium extract, while the other served as a control. The animals were divided into two groups: in one, A. millefolium (150 mg/kg) was applied to the first incision, and in the other, to the second incision. Liver biopsies were collected after 4, 6, and 8 weeks.

Results: Application of A. millefolium to liver incisions, whether first or second, significantly reduced bleeding time (by 36.1% and 31.9%, respectively). Histopathological analysis showed no signs of toxicity or hepatic damage after 4, 6, and 8 weeks in the female rats.

Conclusion: The study confirms the hemostatic effect of the hydroalcoholic extract of A. millefolium in localized bleeding and establishes its safety for topical use.

背景和目的:本研究旨在证明蓍草水醇提取物对局部出血的止血效果,并评估其在大鼠肝脏局部应用的安全性:将 A. millefolium 的气生部分在甲醇中浸泡两天。12 只体重 120-220 克的雌性 Wistar 大鼠接受了麻醉和开腹手术。暴露肝脏,切开两个切口以诱导出血。一个切口用浸泡过 A. millefolium 提取物的海绵处理,另一个切口作为对照。动物被分为两组:一组在第一个切口处涂抹 A. millefolium(150 毫克/千克),另一组在第二个切口处涂抹 A. millefolium(150 毫克/千克)。4周、6周和8周后收集肝脏活组织切片:结果:在肝脏切口(无论是第一切口还是第二切口)上涂抹 A. millefolium 能显著缩短出血时间(分别缩短了 36.1% 和 31.9%)。组织病理学分析表明,雌性大鼠在 4、6 和 8 周后未出现毒性或肝损伤迹象:该研究证实了 A. millefolium 水醇提取物对局部出血的止血效果,并确定了其局部使用的安全性。
{"title":"Safety and hemostatic effect of <i>Achillea millefolium</i> L. in localized bleeding.","authors":"Amin Bagheri, Gholamreza Amin, Seyed Mohammad Tavangar, Matineh Heidari, Jamshid Bagheri","doi":"10.14744/hf.2022.2022.0041","DOIUrl":"10.14744/hf.2022.2022.0041","url":null,"abstract":"<p><strong>Background and aim: </strong>This study aims to demonstrate the hemostatic effect of the hydroalcoholic extract of <i>Achillea millefolium</i> L. in localized bleeding and to assess the safety of its topical application on rat liver.</p><p><strong>Materials and methods: </strong>The aerial parts of <i>A. millefolium</i> were macerated in methanol for two days. Twelve female Wistar rats, weighing 120-220 g, underwent anesthesia and laparotomy. The liver was exposed, and two incisions were made to induce bleeding. One incision was treated with a sponge soaked in <i>A. millefolium</i> extract, while the other served as a control. The animals were divided into two groups: in one, <i>A. millefolium</i> (150 mg/kg) was applied to the first incision, and in the other, to the second incision. Liver biopsies were collected after 4, 6, and 8 weeks.</p><p><strong>Results: </strong>Application of <i>A. millefolium</i> to liver incisions, whether first or second, significantly reduced bleeding time (by 36.1% and 31.9%, respectively). Histopathological analysis showed no signs of toxicity or hepatic damage after 4, 6, and 8 weeks in the female rats.</p><p><strong>Conclusion: </strong>The study confirms the hemostatic effect of the hydroalcoholic extract of <i>A. millefolium</i> in localized bleeding and establishes its safety for topical use.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 1","pages":"25-27"},"PeriodicalIF":1.2,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809340/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571409","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Scotch pine-induced liver injury: A case report. 苏格兰松引起的肝损伤:病例报告
IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-16 eCollection Date: 2024-01-01 DOI: 10.14744/hf.2022.2022.0046
Kadir Intas

Herbal medicines are widely used worldwide to treat minor ailments and prevent disease. Scotch pine (Pinus sylvestris) has many medicinal applications but is most well-known for its antiseptic properties and beneficial effects on the respiratory system. Herbal products can cause adverse side effects like liver injury, which is referred to as herb-induced liver damage (HILI). In this article, we present a patient who used Scotch pine to treat asthma and developed HILI. To the best of our knowledge, this is the first case of Scotch pine-related HILI described in the literature.

草药在世界各地被广泛用于治疗小病和预防疾病。苏格兰松(Pinus sylvestris)有许多药用价值,但最著名的是它的杀菌特性和对呼吸系统的有益作用。草药产品可能会导致肝损伤等不良副作用,这种副作用被称为草药引起的肝损伤(HILI)。本文介绍了一位使用苏格兰松治疗哮喘并导致 HILI 的患者。据我们所知,这是文献中描述的第一例与苏格兰松相关的 HILI。
{"title":"Scotch pine-induced liver injury: A case report.","authors":"Kadir Intas","doi":"10.14744/hf.2022.2022.0046","DOIUrl":"10.14744/hf.2022.2022.0046","url":null,"abstract":"<p><p>Herbal medicines are widely used worldwide to treat minor ailments and prevent disease. Scotch pine (<i>Pinus sylvestris</i>) has many medicinal applications but is most well-known for its antiseptic properties and beneficial effects on the respiratory system. Herbal products can cause adverse side effects like liver injury, which is referred to as herb-induced liver damage (HILI). In this article, we present a patient who used Scotch pine to treat asthma and developed HILI. To the best of our knowledge, this is the first case of Scotch pine-related HILI described in the literature.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 1","pages":"47-48"},"PeriodicalIF":1.2,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809342/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571413","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Changing trends in the etiology of liver transplantation in Turkiye: A multicenter study. 土耳其肝移植病因的变化趋势:一项多中心研究。
IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-16 eCollection Date: 2024-01-01 DOI: 10.14744/hf.2023.2023.0010
Mesut Akarsu, Suleyman Dolu, Murat Harputluoglu, Sezai Yilmaz, Murat Akyildiz, Genco Gencdal, Kamil Yalcin Polat, Dinc Dincer, Haydar Adanir, Ilker Turan, Fulya Gunsar, Zeki Karasu, Hale Gokcan, Sedat Karademir, Gokhan Kabacam, Meral Akdogan Kayhan, Murat Kiyici, Murat Taner Gulsen, Yasemin Balaban, Ahmet Bulent Dogrul, Ali Senkaya, Zeynep Melekoglu Ellik, Fatih Eren, Ramazan Idilman

Background and aim: This study aimed to identify the indications for liver transplantation (LT) based on underlying etiology and to characterize the patients who underwent LT.

Materials and methods: We conducted a multicenter cross-sectional observational study across 11 tertiary centers in Turkiye from 2010 to 2020. The study included 5,080 adult patients.

Results: The mean age of patients was 50.3±15.2 years, with a predominance of female patients (70%). Chronic viral hepatitis (46%) was the leading etiological factor, with Hepatitis B virus infection at 35%, followed by cryptogenic cirrhosis (24%), Hepatitis C virus infection (8%), and alcohol-related liver disease (ALD) (6%). Post-2015, there was a significant increase in both the number of liver transplants and the proportion of living donor liver transplants (p<0.001). A comparative analysis of patient characteristics before and after 2015 showed a significant decline in viral hepatitis-related LT (p<0.001), whereas fatty liver disease-related LT significantly increased (p<0.001).

Conclusion: Chronic viral hepatitis continues to be the primary indication for LT in Turkiye. However, the proportions of non-alcoholic fatty liver disease (NAFLD) and ALD-related LT have seen an upward trend over the years.

背景和目的:本研究旨在根据潜在病因确定肝移植(LT)的适应症,并描述接受肝移植的患者的特征:从 2010 年到 2020 年,我们在土耳其的 11 个三级中心开展了一项多中心横断面观察研究。研究纳入了 5080 名成年患者:患者的平均年龄为(50.3±15.2)岁,女性患者占多数(70%)。慢性病毒性肝炎(46%)是主要病因,其中乙型肝炎病毒感染占 35%,其次是隐源性肝硬化(24%)、丙型肝炎病毒感染(8%)和酒精相关性肝病(6%)。2015年后,肝移植的数量和活体肝移植的比例都有显著增加(p结论:在土耳其,慢性病毒性肝炎仍然是肝移植的主要适应症。不过,非酒精性脂肪肝(NAFLD)和ALD相关的LT比例近年来呈上升趋势。
{"title":"Changing trends in the etiology of liver transplantation in Turkiye: A multicenter study.","authors":"Mesut Akarsu, Suleyman Dolu, Murat Harputluoglu, Sezai Yilmaz, Murat Akyildiz, Genco Gencdal, Kamil Yalcin Polat, Dinc Dincer, Haydar Adanir, Ilker Turan, Fulya Gunsar, Zeki Karasu, Hale Gokcan, Sedat Karademir, Gokhan Kabacam, Meral Akdogan Kayhan, Murat Kiyici, Murat Taner Gulsen, Yasemin Balaban, Ahmet Bulent Dogrul, Ali Senkaya, Zeynep Melekoglu Ellik, Fatih Eren, Ramazan Idilman","doi":"10.14744/hf.2023.2023.0010","DOIUrl":"10.14744/hf.2023.2023.0010","url":null,"abstract":"<p><strong>Background and aim: </strong>This study aimed to identify the indications for liver transplantation (LT) based on underlying etiology and to characterize the patients who underwent LT.</p><p><strong>Materials and methods: </strong>We conducted a multicenter cross-sectional observational study across 11 tertiary centers in Turkiye from 2010 to 2020. The study included 5,080 adult patients.</p><p><strong>Results: </strong>The mean age of patients was 50.3±15.2 years, with a predominance of female patients (70%). Chronic viral hepatitis (46%) was the leading etiological factor, with Hepatitis B virus infection at 35%, followed by cryptogenic cirrhosis (24%), Hepatitis C virus infection (8%), and alcohol-related liver disease (ALD) (6%). Post-2015, there was a significant increase in both the number of liver transplants and the proportion of living donor liver transplants (p<0.001). A comparative analysis of patient characteristics before and after 2015 showed a significant decline in viral hepatitis-related LT (p<0.001), whereas fatty liver disease-related LT significantly increased (p<0.001).</p><p><strong>Conclusion: </strong>Chronic viral hepatitis continues to be the primary indication for LT in Turkiye. However, the proportions of non-alcoholic fatty liver disease (NAFLD) and ALD-related LT have seen an upward trend over the years.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 1","pages":"3-6"},"PeriodicalIF":1.2,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809344/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571354","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Evidence-based herbal treatments in liver diseases. 肝脏疾病的循证草药治疗。
IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-16 eCollection Date: 2024-01-01 DOI: 10.14744/hf.2022.2022.0052
Methiye Mancak, Dudu Altintas, Yasemin Balaban, Ufuk Koca Caliskan

The liver is the main organ for metabolic and detoxification reactions in the body. Therefore, its diseases can be associated with both metabolic disorders, such as insulin resistance, obesity, diabetes, or dyslipidemia, and exogenous insults such as drugs, xenobiotics, or alcohol. Indeed, lifestyle changes are the primary approaches for the prevention and treatment of liver diseases. Since ancient times, herbals have also been used for preventive and therapeutic purposes, because of their anti-apoptotic, anti-inflammatory, and antioxidant effects. Here, the literature was reviewed for potential therapeutic effects of plants and their compounds by including in vitro and in vivo studies, as well as clinical trials. Although the available data imply some beneficial roles of herbals on the liver, the indications and posology of specific plants need to be clarified through multicenter, randomized clinical trials.

肝脏是人体进行新陈代谢和解毒反应的主要器官。因此,肝脏疾病既可能与胰岛素抵抗、肥胖、糖尿病或血脂异常等代谢紊乱有关,也可能与药物、异种生物或酒精等外源性损伤有关。事实上,改变生活方式是预防和治疗肝病的主要方法。自古以来,草药也被用于预防和治疗目的,因为它们具有抗凋亡、抗炎和抗氧化作用。本文通过体外和体内研究以及临床试验,对植物及其化合物的潜在治疗效果进行了文献综述。虽然现有数据表明草药对肝脏有一定的益处,但具体植物的适应症和药理作用还需要通过多中心、随机临床试验加以明确。
{"title":"Evidence-based herbal treatments in liver diseases.","authors":"Methiye Mancak, Dudu Altintas, Yasemin Balaban, Ufuk Koca Caliskan","doi":"10.14744/hf.2022.2022.0052","DOIUrl":"10.14744/hf.2022.2022.0052","url":null,"abstract":"<p><p>The liver is the main organ for metabolic and detoxification reactions in the body. Therefore, its diseases can be associated with both metabolic disorders, such as insulin resistance, obesity, diabetes, or dyslipidemia, and exogenous insults such as drugs, xenobiotics, or alcohol. Indeed, lifestyle changes are the primary approaches for the prevention and treatment of liver diseases. Since ancient times, herbals have also been used for preventive and therapeutic purposes, because of their anti-apoptotic, anti-inflammatory, and antioxidant effects. Here, the literature was reviewed for potential therapeutic effects of plants and their compounds by including <i>in vitro</i> and <i>in vivo</i> studies, as well as clinical trials. Although the available data imply some beneficial roles of herbals on the liver, the indications and posology of specific plants need to be clarified through multicenter, randomized clinical trials.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 1","pages":"50-60"},"PeriodicalIF":1.2,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809338/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Addressing the looming epidemic of metabolic dysfunction-associated steatotic liver disease in Pakistan: A call for action. 应对巴基斯坦迫在眉睫的代谢功能障碍相关性脂肪肝疫情:行动呼吁。
IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-16 eCollection Date: 2024-01-01 DOI: 10.14744/hf.2023.2023.0045
Lubna Kamani, Adeel Rahat, Yusuf Yilmaz
{"title":"Addressing the looming epidemic of metabolic dysfunction-associated steatotic liver disease in Pakistan: A call for action.","authors":"Lubna Kamani, Adeel Rahat, Yusuf Yilmaz","doi":"10.14744/hf.2023.2023.0045","DOIUrl":"10.14744/hf.2023.2023.0045","url":null,"abstract":"","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 1","pages":"1-2"},"PeriodicalIF":1.2,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809346/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571233","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Effect of probiotics supplementation on liver stiffness and steatosis in patients with NAFLD. 补充益生菌对非酒精性脂肪肝患者肝硬变和脂肪变性的影响
IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-16 eCollection Date: 2024-01-01 DOI: 10.14744/hf.2022.2022.0003
Shahinul Alam, Pallab Kumar Datta, Mahabubul Alam, Mohammad Jahid Hasan

Background and aim: To compare the effects of probiotics on liver stiffness and steatosis in obese and non-obese patients with nonalcoholic fatty liver disease (NAFLD),the pragmatic clinical trial included 50 obese body mass index (BMI) ≥25 kg/m2 and 50 non-obese NAFLD BMI <25 kg/m2 age and sex-matched patients.

Materials and methods: Fibroscan with controlled attenuated parameter (CAP) was done at day 0 and at the end of 6 months. Probiotics supplementation was provided for both groups for 6 months along with lifestyle modifications.

Results: At inclusion, both groups had comparable characteristics except BMI, metabolic syndrome and waist circumference (WC). Beneficial changes occurred in BMI (p=0.024), WC (p=0.045), ALT (p=0.024), total cholesterol (p=0.016), LDL (p=0.025) and triglyceride (p=0.021) of obese group, systolic blood pressure (p=0.003) and LDL level (p=0.018) in non-obese group. No significant change was observed in liver enzymes and glycemic profiles. Significant improvement in CAP was observed in both groups. But after adjusting for changes in BMI and WC, the change in CAP among non-obese participants were significantly higher compared to obese, mean change of 19.33±48.87 and 16.02±51.58 dB/m in non-obese and obese patients, respectively; p=0.044).

Conclusion: Probiotics improve CAP/ steatosis in both obese and non-obese NAFLD patients and improvement was higher in non-obese, irrespective of BMI change.

背景和目的:为了比较益生菌对肥胖和非肥胖非酒精性脂肪肝(NAFLD)患者肝脏僵硬度和脂肪变性的影响,该实用临床试验纳入了50名体重指数(BMI)≥25 kg/m2的肥胖患者和50名年龄和性别匹配的非肥胖NAFLD BMI 2患者:在第 0 天和 6 个月结束时使用受控衰减参数(CAP)进行纤维扫描。两组患者均补充益生菌 6 个月,同时改变生活方式:除了体重指数(BMI)、代谢综合征和腰围(WC)外,两组在纳入时的特征具有可比性。肥胖组的体重指数(p=0.024)、腰围(p=0.045)、谷丙转氨酶(p=0.024)、总胆固醇(p=0.016)、低密度脂蛋白(p=0.025)和甘油三酯(p=0.021),以及非肥胖组的收缩压(p=0.003)和低密度脂蛋白水平(p=0.018)都发生了有益的变化。肝酶和血糖谱未观察到明显变化。两组的 CAP 均有明显改善。但在调整体重指数(BMI)和腹围(WC)的变化后,非肥胖参与者的 CAP 变化明显高于肥胖者,非肥胖患者和肥胖患者的平均变化分别为(19.33±48.87)和(16.02±51.58)dB/m;P=0.044):结论:益生菌可改善肥胖和非肥胖非酒精性脂肪肝患者的CAP/脂肪变性,非肥胖患者的改善程度更高,与体重指数的变化无关。
{"title":"Effect of probiotics supplementation on liver stiffness and steatosis in patients with NAFLD.","authors":"Shahinul Alam, Pallab Kumar Datta, Mahabubul Alam, Mohammad Jahid Hasan","doi":"10.14744/hf.2022.2022.0003","DOIUrl":"10.14744/hf.2022.2022.0003","url":null,"abstract":"<p><strong>Background and aim: </strong>To compare the effects of probiotics on liver stiffness and steatosis in obese and non-obese patients with nonalcoholic fatty liver disease (NAFLD),the pragmatic clinical trial included 50 obese body mass index (BMI) ≥25 kg/m<sup>2</sup> and 50 non-obese NAFLD BMI <25 kg/m<sup>2</sup> age and sex-matched patients.</p><p><strong>Materials and methods: </strong>Fibroscan with controlled attenuated parameter (CAP) was done at day 0 and at the end of 6 months. Probiotics supplementation was provided for both groups for 6 months along with lifestyle modifications.</p><p><strong>Results: </strong>At inclusion, both groups had comparable characteristics except BMI, metabolic syndrome and waist circumference (WC). Beneficial changes occurred in BMI (p=0.024), WC (p=0.045), ALT (p=0.024), total cholesterol (p=0.016), LDL (p=0.025) and triglyceride (p=0.021) of obese group, systolic blood pressure (p=0.003) and LDL level (p=0.018) in non-obese group. No significant change was observed in liver enzymes and glycemic profiles. Significant improvement in CAP was observed in both groups. But after adjusting for changes in BMI and WC, the change in CAP among non-obese participants were significantly higher compared to obese, mean change of 19.33±48.87 and 16.02±51.58 dB/m in non-obese and obese patients, respectively; p=0.044).</p><p><strong>Conclusion: </strong>Probiotics improve CAP/ steatosis in both obese and non-obese NAFLD patients and improvement was higher in non-obese, irrespective of BMI change.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 1","pages":"18-24"},"PeriodicalIF":1.2,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809339/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571372","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
From hepatomegaly to POEMS syndrome: A case report. 从肝肿大到 POEMS 综合征:病例报告
IF 1.2 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2024-01-16 eCollection Date: 2024-01-01 DOI: 10.14744/hf.2022.2022.0035
Yavuz Ozden, Sebnem Gursoy

We present a case of POEMS syndrome from Turkiye, a rare, multisystemic condition resulting from plasma cell dyscrasia. POEMS is an acronym representing its cardinal features: Peripheral neuropathy; Organomegaly; Endocrinopathy; Monoclonal plasma-cell proliferative disorder; and Skin changes. The syndrome has an estimated prevalence of 0.3 per 100,000 individuals and typically manifests in the fifth or sixth decade of life. Progressive peripheral neuropathy is the syndrome's most prominent symptom. To ensure an accurate diagnosis, a thorough medical history, physical examination, and comprehensive diagnostic evaluations are essential. These evaluations should include serum immunoelectrophoresis, serum cytokines, and growth factors, a skeletal survey, and a bone marrow biopsy. Early recognition and treatment of POEMS syndrome are crucial to prevent debilitating progression and to optimize clinical outcomes.

我们介绍了一例来自土耳其的 POEMS 综合征病例,这是一种罕见的、由浆细胞异常引起的多系统疾病。POEMS 是一个首字母缩写词,代表其主要特征:周围神经病变;器官肿大;内分泌病变;单克隆浆细胞增殖障碍;皮肤改变。据估计,该综合征的发病率为每 10 万人中有 0.3 人患病,通常出现在患者的第五或第六个十年。进行性周围神经病变是该综合征最突出的症状。为确保准确诊断,全面的病史、体格检查和综合诊断评估至关重要。这些评估应包括血清免疫电泳、血清细胞因子和生长因子、骨骼检查和骨髓活检。POEMS 综合征的早期识别和治疗对于防止病情恶化和优化临床疗效至关重要。
{"title":"From hepatomegaly to POEMS syndrome: A case report.","authors":"Yavuz Ozden, Sebnem Gursoy","doi":"10.14744/hf.2022.2022.0035","DOIUrl":"10.14744/hf.2022.2022.0035","url":null,"abstract":"<p><p>We present a case of POEMS syndrome from Turkiye, a rare, multisystemic condition resulting from plasma cell dyscrasia. POEMS is an acronym representing its cardinal features: Peripheral neuropathy; Organomegaly; Endocrinopathy; Monoclonal plasma-cell proliferative disorder; and Skin changes. The syndrome has an estimated prevalence of 0.3 per 100,000 individuals and typically manifests in the fifth or sixth decade of life. Progressive peripheral neuropathy is the syndrome's most prominent symptom. To ensure an accurate diagnosis, a thorough medical history, physical examination, and comprehensive diagnostic evaluations are essential. These evaluations should include serum immunoelectrophoresis, serum cytokines, and growth factors, a skeletal survey, and a bone marrow biopsy. Early recognition and treatment of POEMS syndrome are crucial to prevent debilitating progression and to optimize clinical outcomes.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 1","pages":"44-46"},"PeriodicalIF":1.2,"publicationDate":"2024-01-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10809343/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139571379","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The pleiotropic approach to coronavirus disease-19 pathogenesis: The impact of liver diseases associated host genetic variants. 冠状病毒疾病-19 发病机制的多态性方法:与肝脏疾病相关的宿主基因变异的影响。
IF 0.8 Q4 GASTROENTEROLOGY & HEPATOLOGY Pub Date : 2023-12-07 eCollection Date: 2024-01-01 DOI: 10.14744/hf.2023.2023.0018
Eren Sahin, Ali Dag, Fatih Eren

Coronavirus disease-2019 (COVID-19) is a novel multisystemic viral disease caused pandemic. The disease impact involves liver and associated systems. Undoubtedly, host genetic background influences the predisposition and prediction of infection. Variants among human populations might increase susceptibility or protect against severe outcomes. In this manner, rs738409 variant of patatin-like phospholipase domain-containing protein 3 gene appears to be protective in some populations in spite of its aggravating effect on non-alcoholic fatty liver diseases (NAFLDs) and steatohepatitis. DRB1*15:01 allele of human leukocyte antigen is associated with protective effect in European and Japanese populations. DRB1*03:01 contrarily increases the susceptibility of severe COVID-19 infection in European populations. rs1260326 in glucokinase regulatory protein gene, rs112875651 in tribbles homolog 1 gene, rs429358 in apolipoprotein 1, and rs58542926 in transmembrane 6 superfamily 2 alleles are found related with NAFLD and obesity; thus, hypercoagulability and severe COVID-19 outcomes. In chronic or acute liver diseases, comorbid syndromes are the key factors to explain increased severity. There might not be a direct association between the variant and severe COVID-19 infection. As it is concluded, there are genes and variants known and unknown yet to be studied to reveal the association with disease severity.

冠状病毒病-2019(COVID-19)是一种引起大流行的新型多系统病毒性疾病。疾病影响涉及肝脏和相关系统。毫无疑问,宿主的遗传背景会影响感染的易感性和预测。人群中的变异可能会增加易感性或防止严重后果的发生。因此,在某些人群中,类磷脂酶域含蛋白 3 基因的 rs738409 变异似乎具有保护作用,尽管它对非酒精性脂肪肝和脂肪性肝炎有加重作用。在欧洲和日本人群中,人类白细胞抗原的 DRB1*15:01 等位基因具有保护作用。葡萄糖激酶调节蛋白基因中的 rs1260326、tribbles homolog 1 基因中的 rs112875651、载脂蛋白 1 中的 rs429358 和跨膜 6 超家族 2 等位基因中的 rs58542926 与非酒精性脂肪肝和肥胖有关,因此与高凝状态和严重 COVID-19 结果有关。在慢性或急性肝病中,合并症是导致病情加重的关键因素。变异基因与严重的 COVID-19 感染之间可能没有直接联系。综上所述,还有一些已知和未知的基因和变异体有待研究,以揭示它们与疾病严重程度的关系。
{"title":"The pleiotropic approach to coronavirus disease-19 pathogenesis: The impact of liver diseases associated host genetic variants.","authors":"Eren Sahin, Ali Dag, Fatih Eren","doi":"10.14744/hf.2023.2023.0018","DOIUrl":"10.14744/hf.2023.2023.0018","url":null,"abstract":"<p><p>Coronavirus disease-2019 (COVID-19) is a novel multisystemic viral disease caused pandemic. The disease impact involves liver and associated systems. Undoubtedly, host genetic background influences the predisposition and prediction of infection. Variants among human populations might increase susceptibility or protect against severe outcomes. In this manner, rs738409 variant of patatin-like phospholipase domain-containing protein 3 gene appears to be protective in some populations in spite of its aggravating effect on non-alcoholic fatty liver diseases (NAFLDs) and steatohepatitis. DRB1*15:01 allele of human leukocyte antigen is associated with protective effect in European and Japanese populations. DRB1*03:01 contrarily increases the susceptibility of severe COVID-19 infection in European populations. rs1260326 in glucokinase regulatory protein gene, rs112875651 in tribbles homolog 1 gene, rs429358 in apolipoprotein 1, and rs58542926 in transmembrane 6 superfamily 2 alleles are found related with NAFLD and obesity; thus, hypercoagulability and severe COVID-19 outcomes. In chronic or acute liver diseases, comorbid syndromes are the key factors to explain increased severity. There might not be a direct association between the variant and severe COVID-19 infection. As it is concluded, there are genes and variants known and unknown yet to be studied to reveal the association with disease severity.</p>","PeriodicalId":29722,"journal":{"name":"Hepatology Forum","volume":"5 2","pages":"93-96"},"PeriodicalIF":0.8,"publicationDate":"2023-12-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10936119/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140132736","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Hepatology Forum
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1